Successful suppression using Rituximab of a factor VIII inhibitor in a boy with severe congenital haemophilia: An example of a significant decrease of treatment costs

• References

• 1 Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients. A review of recent studies of recombinant and plasma-derived Factor VIII concentrates. Haemophilia 1999; 5: 145-54.
• 2 Knight C, Paisley S, Wight J. et al. Economic modeling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia 2003; 9: 521-40.
• 3 Virgolini L, Marzocchi V. Rituximab in autoimmune diseases. Biomed Pharmacother 2004; 58: 299-309.
• 4 Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived Factor VIII/von Willebrand Factor concentrates in the treatment of Hemophilia A patients. Haematologica 2003; (Suppl. 09) 21-5.
• 5 Wiestner A, Cho HJ, Asch AS. et al. Rituximab in the treatment of acquired Factor VIII inhibitors. Blood 2002; 100: 3426-8.
• 6 Mathias M, Khair K, Hann I. et al. Rituximab in the treatment of alloimmune Factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004; 125: 366-8.
• 7 Haya S, López MF, Aznar JA. et al. and the Spanish Immune Tolerance Group. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia 2001; 7: 154-9.
• 8 Freiburghaus C, Berntorp E, Ekman M. et al. Tolerance induction using the Malmo treatment model 1982–1995. Haemophilia 1999; 5: 32-9.